SOLICITATION NOTICE
66 -- Proprietary Custom Antibodies, Buffers, and Blocking Reagents
- Notice Date
- 9/12/2013
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse, Station Support/Simplified Acquisitions, 31 Center Drive, Room 1B59, Bethesda, Maryland, 20892
- ZIP Code
- 20892
- Solicitation Number
- 3038227
- Archive Date
- 10/3/2013
- Point of Contact
- Jasmine D Snoddy, Phone: 301 594 1571
- E-Mail Address
-
snoddyj@mail.nih.gov
(snoddyj@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The solicitation number is 3038227 and the solicitation is issued as a pre-solicitation notice of intent to award a non-competitive order to Cisbio Bioassays UA, 135 South Road, Bedford, MA, 01730. This acquisition is conducted under the authority of the Federal Acquisition Regulation (A FAR) Part 13-Simplified Acquisition Procedures, Subpart 13.106 (b) (1), Soliciting from a single source and is not expected to exceed the simplified acquisition threshold. Contracts awarded using FAR Part 13-Simplified Acquisition Procedures are exempt from the requirement of FAR Part 6-Competition Requirements. The solicitation document and incorporated provisions and clauses are those in effect through Federal Acquisition Circular 2005-69, dated August 1, 2013. A notice regarding any set-aside restrictions, the associated NAICS code 334516 and the small business size standard 500 employees. This acquisition is being conducted in accordance with the procedures of FAR Part 13-Simplified Acquisition Procedures. The National Institute on Drug Abuse (NIDA), Station Support/Simplified Acquisition (SS/SA) Branch has a requirement on behalf of National Center for Advancing Translational Science (NCATS) to purchase proprietary custom antibodies, buffers, and blocking reagents. This request will be used to screen the Tox21 10K library with an assay for DNA damage. The assay works by detecting the phosphorylation of histone H2AX by labeling antibodies with donor and acceptor fluors (europium cryptate and d2) to enable homogenous detection in a high throughput environment using Cisbio's HTRF technology. The only technology available for pH2AX detection is immunofluorescence, which requires may incubation and wash steps. HTRF is a homogeneous and non radio-isotopic technology. This HTRF technology has been developed and also successfully used for NCATS online validation for this homogenous (no wash steps) DNA damage detection assay that was just approved by NCATS review group. When DNA double strand breaks occur, histone H2AX is phosphorylated and moves to the site of the damage. This assay will be used in CHO cells as marker for DNA damage. Homogeneous assays, like HTRF, are key to efficient and effective screening. Our Tox21 research group, as well as other NCATS Biology groups, has used this Cisbio HTRF technology for several large screens in 1536 well format, with high reproducibility and low false positives, compared to other technologies. For example, the HTFR TNF alpha assay was used to screen the LOPAC and FDA libraries in 1536 well format with great success. NCATS will use this assay to screen compounds from EPA/NTP/FDA. This is the Tox21 collaboration work between NCGC and NTP/EPA/FDA. HTRF labeling technology is exclusive to Cisbio as this specific labeling technology, with Europium cryptate and d2 is not available at any other company. In addition, Cisbio holds a patent for using the ratio of the signals for normalization of the assay. The Defense Priorities and Allocations System (DPAS) is not applicable to this requirement. The synopsis is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this notice. Responses to this notice shall contain sufficient information to establish the interested parties' bona-fide capabilities for fulfilling the requirement and include: unit price, list price, shipping and handling costs, the delivery period after contract award, the prompt payment discount terms, the F.O.B. Point (Destination or Origin), the Dun & Bradstreet Number (DUNS), the Taxpayer Identification Number (TIN), and the certification of business size. All offerors must have an active registration in the System for Award Management (SAM) www.sam.gov." All responses must be received by September 18, 2013 12:00PM EST and must reference number 3038227. Responses may be submitted electronically to Jasmine Snoddy, Contract Specialist and email at Snoddyj@mail.nih.gov or by U.S. mail to the National Institute of Drug Abuse (NIDA), Station Support/Simplified Acquisition Branch, 31 Center Drive, Room 1B59, Bethesda, Maryland 20892-2080, Attention: Jasmine Snoddy. Fax responses will not be accepted. "All responsible sources may submit a bid, proposal, or quotation which shall be considered by the agency." The name and telephone number of the individual to contact for information regarding the solicitation is Jasmine Snoddy and telephone number is (301) 594-1571.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/NIDA-2/3038227/listing.html)
- Place of Performance
- Address: Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03185613-W 20130914/130912235548-04089b9c71cbd592bb6306ffe0e30384 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |